Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Shi, Chenchen ^a   Li, Haipeng ^b   Yang, Yifu ^a   Hou, Lifei ^c  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ DERIVATIVE; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; DRUG MECHANISM; HUMAN; IMMUNOREGULATION; IN VITRO STUDY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; B LYMPHOCYTE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; HYPERSENSITIVITY; IMMUNE SYSTEM; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MOUSE; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIMALARIALS; ARTEMISININS; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; B-LYMPHOCYTES; DRUG DESIGN; HUMANS; HYPERSENSITIVITY; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, TRANSGENIC; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 84928808854     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/435713     Document Type: Review

References (41)

1. Y. Li, "Qinghaosu (artemisinin): chemistry and pharmacology," Acta Pharmacologica Sinica, vol. 33, no. 9, pp. 1141-1146, 2012.
2. N. J. White, "Qinghaosu (artemisinin): the price of success," Science, vol. 320, no. 5874, pp. 330-334, 2008.
3. M. B. van Hensbroek, E. Onyiorah, S. Jaffar et al., "A trial of artemether or quinine in children with cerebral malaria," The New England Journal of Medicine, vol. 335, no. 2, pp. 69-75, 1996.
4. W. L. Zhou, J. M. Wu, Q. L. Wu et al., "A novel artemisinin derivative, 3-(12-beta-artemisininoxy) phenoxyl succinic acid (SM735), mediates immunosuppressive effects in vitro and in vivo," Acta Pharmacologica Sinica, vol. 26, no. 11, pp. 1352-1358, 2005.
5. J.-X. Wang, L.-F. Hou, Y. Yang, W. Tang, Y. Li, and J.-P. Zuo, "SM905, an artemisinin derivative, inhibited NO and proinflammatory cytokine production by suppressing MAPK and NF-B pathways in RAW 264.7 macrophages," Acta Pharmacologica Sinica, vol. 30, no. 10, pp. 1428-1435, 2009.
6. J.-X. Wang, W. Tang, Z.-S. Yang et al., "Suppressive effect of a novel water-soluble artemisinin derivative SM905 on T cell activation and proliferation in vitro and in vivo," European Journal of Pharmacology, vol. 564, no. 1-3, pp. 211-218, 2007.
7. J.-X. Wang, W. Tang, R. Zhou et al., "The new water-soluble artemisinin derivative SM905 ameliorates collagen-induced arthritis by suppression of inflammatory and Th17 responses," British Journal of Pharmacology, vol. 153, no. 6, pp. 1303-1310, 2008.
8. Y. G. Zhao, Y. Wang, Z. Guo et al., "Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway," Journal of Immunology, vol. 189, no. 9, pp. 4417-4425, 2012.
9. L.-F. Hou, S.-J. He, X. Li et al., "Sm934 treated lupus-prone NZB×NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development," PLoS ONE, vol. 7, no. 2, Article ID e32424, 2012.
10. L.-F. Hou, S.-J. He, X. Li et al., "Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses," Arthritis and Rheumatism, vol. 63, no. 8, pp. 2445-2455, 2011.
11. L.-F. Hou, S.-J. He, J.-X. Wang et al., "SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo," International Immunopharmacology, vol. 9, no. 13-14, pp. 1509-1517, 2009.
12. X. Li, T.-T. Li, X.-H. Zhang et al., "Artemisinin analogue SM934 ameliorates murine experimental autoimmune encephalomyelitis through enhancing the expansion and functions of regulatory T cell," PLoS ONE, vol. 8, no. 8, Article ID e74108, 2013.
13. P. L. Olliaro, R. K. Haynes, B. Meunier, and Y. Yuthavong, "Possible modes of action of the artemisinin-type compounds," Trends in Parasitology, vol. 17, no. 3, pp. 122-126, 2001.
14. J. L. Vennerstrom, S. Arbe-Barnes, R. Brun et al., "Identification of an antimalarial synthetic trioxolane drug development candidate," Nature, vol. 430, no. 7002, pp. 900-904, 2004.
15. A. Robert, F. Benoit-Vical, C. Claparols, and B. Meunier, "The antimalarial drug artemisinin alkylates heme in infected mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13676-13680, 2005.
16. A. E. Mercer, J. L. Maggs, X.-M. Sun et al., "Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds," The Journal of Biological Chemistry, vol. 282, no. 13, pp. 9372-9382, 2007.
17. J. Golenser, J. H. Waknine, M. Krugliak, N. H. Hunt, and G. E. Grau, "Current perspectives on the mechanism of action of artemisinins," International Journal for Parasitology, vol. 36, no. 14, pp. 1427-1441, 2006.
18. J. Alberola-Ila, S. Takaki, J. D. Kerner, and R. M. Perlmutter, "Differential signaling by lymphocyte antigen receptors," Annual Review of Immunology, vol. 15, pp. 125-154, 1997.
19. N. C. Lea, S. J. Orr, K. Stoeber et al., "Commitment point during G0 → G1 that controls entry into the cell cycle," Molecular and Cellular Biology, vol. 23, no. 7, pp. 2351-2361, 2003.
20. A. Van der Borght, P. Geusens, J. Raus, and P. Stinissen, "The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies," Seminars in Arthritis and Rheumatism, vol. 31, no. 3, pp. 160-175, 2001.
21. C. J. Hedegaard, M. Krakauer, K. Bendtzen, H. Lund, F. Sellebjerg, and C. H. Nielsen, "T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis," Immunology, vol. 125, no. 2, pp. 161-169, 2008.
22. J.-X. Wang, W. Tang, L.-P. Shi et al., "Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation," British Journal of Pharmacology, vol. 150, no. 5, pp. 652-661, 2007.
23. Z.-S. Yang, J.-X. Wang, Y. Zhou, J.-P. Zuo, and Y. Li, "Synthesis andimmunosuppressive activity of newartemisinin derivatives. Part 2: 2-[12(beta or alpha)-dihydroartemisinoxymethyl(or 1'- ethyl)]phenoxyl propionic acids and esters," Bioorganic and Medicinal Chemistry, vol. 14, no. 23, pp. 8043-8049, 2006.
24. Z.-S. Yang, W.-L. Zhou, Y. Sui et al., "Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(β or α)- dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters," Journal of Medicinal Chemistry, vol. 48, no. 14, pp. 4608-4617, 2005.
25. J.-X. Zhang, J.-X. Wang, Y. Zhang et al., "Synthesis and immunosuppressive activity of new artemisinin derivatives containing polyethylene glycol group," Yaoxue Xuebao, vol. 41, no. 1, pp. 65-70, 2006.
26. S. Noori, Z. M. Hassan, B. Rezaei, A. Rustaiyan, Z. Habibi, and F. Fallahian, "Artemisinin can inhibit the calmodulin-mediated activation of phosphodiesterase in comparison with Cyclosporin A," International Immunopharmacology, vol. 8, no. 13-14, pp. 1744-1747, 2008.
27. S. Noori, Z. M. Hassan, M. Taghikhani, B. Rezaei, and Z. Habibi, "Dihydroartemisinin can inhibit calmodulin, calmodulindependent phosphodiesterase activity and stimulate cellular immune responses," International Immunopharmacology, vol. 10, no. 2, pp. 213-217, 2010.
28. L. Hou, K. E. Block, H. Huang, and J. Zhang, "Artesunate abolishes germinal center B cells and inhibits autoimmune arthritis," PLoS ONE, vol. 9, no. 8, Article ID e104762, 2014.
29. B. Guruprasad, P. Chaudhary, T. Choedon, and V. L. Kumar, "Artesunate ameliorates functional limitations in Freund's complete adjuvant-induced monoarthritis in rat by maintaining oxidative homeostasis and inhibiting COX-2 expression," Inflammation, 2014.
30. Y. He, J. Fan, H. Lin et al., "The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1α in human rheumatoid arthritis fibroblast-like synoviocyte," Rheumatology International, vol. 31, no. 1, pp. 53-60, 2011.
31. H. Xu, Y. He, X. Yang et al., "Anti-malarial agent artesunate inhibits TNF-α-induced production of proinflammatory cytokines via inhibition of NF-κB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes," Rheumatology, vol. 46, no. 6, pp. 920-926, 2007.
32. A. N. Theofilopoulos and F. J. Dixon, "Murine models of systemic lupus erythematosus," Advances in Immunology, vol. 37, pp. 269-390, 1985.
33. B. Andrews, R. A. Eisenberg, A. N. Theofilopoulos et al., "Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains," The Journal of Experimental Medicine, vol. 148, no. 5, pp. 1198-1215, 1978.
34. W.-D. Li, Y.-J. Dong, Y.-Y. Tu, and Z.-B. Lin, "Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation," International Immunopharmacology, vol. 6, no. 8, pp. 1243-1250, 2006.
35. Z. Wang, J. Qiu, T. B. Guo et al., "Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis," The Journal of Immunology, vol. 179, no. 9, pp. 5958-5965, 2007.
36. C. Cheng, W. E. Ho, F. Y. Goh et al., "Anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway," PLoS ONE, vol. 6, no. 6, Article ID e20932, 2011.
37. C. Cheng, D. S.W. Ng, T. K. Chan et al., "Anti-allergic action of anti-malarial drug artesunate in experimental mast cellmediated anaphylactic models," Allergy, vol. 68, no. 2, pp. 195-203, 2013.
38. S. S. L. Tan, B. Ong, C. Cheng et al., "The antimalarial drug artesunate inhibits primary human cultured airway smooth muscle cell proliferation," The American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 2, pp. 451-458, 2014.
39. U. Eckstein-Ludwig, R. J. Webb, I. D. A. van Goethem et al., "Artemisinins target the SERCA of Plasmodium falciparum," Nature, vol. 424, no. 6951, pp. 957-961, 2003.
40. A.-C. Uhlemann, A. Cameron, U. Eckstein-Ludwig et al., "A single amino acid residue can determine the sensitivity of SERCAs to artemisinins," Nature Structural and Molecular Biology, vol. 12, no. 7, pp. 628-629, 2005.
41. M. Jung, H. Kim, Y. N. Ki, and T. N. Kyoung, "Threedimensional structure of Plasmodium falciparum Ca2+- ATPase(PfATP6) and docking of artemisinin derivatives to PfATP6," Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 12, pp. 2994-2997, 2005.